$614 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 107 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR SERIES TRUSTput | $106,064,000 | – | 1,600,000 | +100.0% | 17.27% | – | |
| New | ISHARES TRput | $57,892,000 | – | 200,000 | +100.0% | 9.43% | – | |
| SRPT | New | SAREPTA THERAPEUTICS INC | $16,154,000 | – | 263,047 | +100.0% | 2.63% | – |
| AMGN | New | AMGEN INC | $10,993,000 | – | 65,900 | +100.0% | 1.79% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $8,578,000 | – | 70,000 | +100.0% | 1.40% | – |
| New | BIOMARIN PHARMACEUTICAL INCcall | $7,402,000 | – | 80,000 | +100.0% | 1.20% | – | |
| AZN | New | ASTRAZENECA PLCsponsored adr | $6,572,000 | – | 200,000 | +100.0% | 1.07% | – |
| AKAOQ | New | ACHAOGEN INC | $6,228,000 | – | 1,300,313 | +100.0% | 1.01% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $6,075,000 | – | 900,000 | +100.0% | 0.99% | – |
| NICE | New | NICE LTDsponsored adr | $5,760,000 | – | 86,040 | +100.0% | 0.94% | – |
| TSRO | New | TESARO INC | $5,012,000 | – | 50,000 | +100.0% | 0.82% | – |
| AVXS | New | AVEXIS INC | $4,121,000 | – | 100,000 | +100.0% | 0.67% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $3,989,000 | – | 284,652 | +100.0% | 0.65% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $3,976,000 | – | 125,000 | +100.0% | 0.65% | – |
| FIS | New | FIDELITY NATL INFORMATION SV | $3,710,000 | – | 48,160 | +100.0% | 0.60% | – |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $3,687,000 | – | 112,500 | +100.0% | 0.60% | – |
| UNP | New | UNION PAC CORP | $3,635,000 | – | 37,275 | +100.0% | 0.59% | – |
| APD | New | AIR PRODS & CHEMS INC | $3,164,000 | – | 21,045 | +100.0% | 0.52% | – |
| New | APPLE INCcall | $2,759,000 | – | 18,500 | +100.0% | 0.45% | – | |
| SNA | New | SNAP ON INC | $2,755,000 | – | 18,130 | +100.0% | 0.45% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $2,672,000 | – | 150,000 | +100.0% | 0.44% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $2,521,000 | – | 166,310 | +100.0% | 0.41% | – |
| VSAR | New | VERSARTIS INC | $2,450,000 | – | 200,000 | +100.0% | 0.40% | – |
| SBUX | New | STARBUCKS CORP | $2,252,000 | – | 41,600 | +100.0% | 0.37% | – |
| ADXS | New | ADVAXIS INC | $2,138,000 | – | 200,000 | +100.0% | 0.35% | – |
| ARDX | New | ARDELYX INC | $1,964,000 | – | 151,813 | +100.0% | 0.32% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $1,847,000 | – | 228,029 | +100.0% | 0.30% | – |
| RPRX | New | REPROS THERAPEUTICS INC | $1,805,000 | – | 863,807 | +100.0% | 0.29% | – |
| NVLS | New | NIVALIS THERAPEUTICS INC | $1,664,000 | – | 204,700 | +100.0% | 0.27% | – |
| BURL | New | BURLINGTON STORES INC | $1,499,000 | – | 18,500 | +100.0% | 0.24% | – |
| VTVT | New | VTV THERAPEUTICS INCcl a | $1,438,000 | – | 200,000 | +100.0% | 0.23% | – |
| MYOK | New | MYOKARDIA INC | $1,360,000 | – | 83,240 | +100.0% | 0.22% | – |
| ACIU | New | AC IMMUNE SA | $1,314,000 | – | 79,800 | +100.0% | 0.21% | – |
| PANW | New | PALO ALTO NETWORKS INC | $1,124,000 | – | 7,052 | +100.0% | 0.18% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $735,000 | – | 100,000 | +100.0% | 0.12% | – |
| ORA | New | ORMAT TECHNOLOGIES INC | $370,000 | – | 7,640 | +100.0% | 0.06% | – |
| ALIM | New | ALIMERA SCIENCES INC | $299,000 | – | 200,715 | +100.0% | 0.05% | – |
| SITE | New | SITEONE LANDSCAPE SUPPLY INC | $288,000 | – | 8,020 | +100.0% | 0.05% | – |
| UNH | New | UNITEDHEALTH GROUP INC | $238,000 | – | 1,700 | +100.0% | 0.04% | – |
| MHK | New | MOHAWK INDS INC | $220,000 | – | 1,100 | +100.0% | 0.04% | – |
| CABO | New | CABLE ONE INC | $216,000 | – | 370 | +100.0% | 0.04% | – |
| LOW | New | LOWES COS INC | $212,000 | – | 2,940 | +100.0% | 0.04% | – |
| HSIC | New | SCHEIN HENRY INC | $163,000 | – | 1,000 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 39 | Q2 2024 | 8.4% |
| MERCK & CO INC NEW | 38 | Q2 2024 | 8.4% |
| NICE Systems Ltd | 30 | Q2 2024 | 4.4% |
| BIOGEN INC | 29 | Q2 2024 | 6.7% |
| PFIZER INC | 28 | Q2 2024 | 9.2% |
| SAREPTA THERAPEUTICS INC | 28 | Q2 2024 | 3.2% |
| JOHNSON & JOHNSON | 27 | Q2 2024 | 8.0% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| SYNDAX PHARMACEUTICALS INC | 25 | Q2 2024 | 3.9% |
| ASTRAZENECA PLC | 24 | Q2 2024 | 7.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Skye Bioscience, Inc. | February 08, 2024 | 1,301,518 | 5.4% |
| Inozyme Pharma, Inc. | February 05, 2024 | 1,562,907 | 2.5% |
| Jasper Therapeutics, Inc. | February 05, 2024 | 7,130,625 | 6.4% |
| Praxis Precision Medicines, Inc. | February 05, 2024 | 328,986 | 3.7% |
| ProMIS Neurosciences Inc. | February 05, 2024 | 1,892,474 | 10.0% |
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| SC 13G | 2024-08-20 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.